Summary & Overview
CPT 0141U: ePlex® BCID Gram-Positive Panel for Rapid Blood Culture Pathogen Detection
CPT code 0141U identifies a proprietary molecular diagnostic assay — the ePlex® BCID gram–positive panel from GenMark Diagnostics — used for rapid detection of multiple gram-positive bacterial targets, select resistance genes, and pan-targets for gram-negative bacteria and Candida from positive blood cultures. As a PLA code, 0141U applies only to this specific commercial test and matters nationally because rapid, targeted pathogen identification can influence antimicrobial management and hospital infection care pathways. Coverage and payment for PLA tests are closely watched by national payers and Medicare due to clinical impact and cost considerations. Key payers discussed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical role of the assay, how CPT code 0141U is used in billing, typical sites of service where the test is performed, and what to expect from national payer engagement. The publication also outlines benchmarking topics and policy considerations relevant to proprietary laboratory analyses, including coding specificity, payer coverage patterns, and implications for laboratory workflow and hospital diagnostic protocols. Data not available in the input for specific payer policies, reimbursement rates, associated taxonomies, and ICD-10 pairings are noted where applicable.
Billing Code Overview
CPT code 0141U is a Proprietary Laboratory Analyses (PLA) code for the ePlex® BCID gram–positive panel (GenMark Diagnostics Inc.). The test uses an automated amplified probe technique for rapid detection of 20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, and 1 pan Candida target from positive blood cultures.
-
Service type: Proprietary molecular diagnostic laboratory test for pathogen and resistance gene detection from positive blood culture specimens
-
Typical site of service: Hospital or independent clinical laboratory processing positive blood cultures for rapid identification of bloodstream infection pathogens and select resistance markers
Clinical & Coding Specifications
Clinical Context
A patient presents to the emergency department with fever, hypotension, and suspected sepsis after a recent central line placement. Blood cultures are obtained and one set flags positive for gram-positive organisms on the automated blood culture instrument. The clinical team requests rapid organism identification and resistance marker detection to guide early antimicrobial therapy. The laboratory receives the positive blood culture bottle and performs the ePlex® BCID gram–positive panel (0141U) using an automated amplified probe platform. Results return within hours, reporting identification of gram-positive bacterial targets and relevant resistance genes (e.g., mecA). The laboratory issues the report to the ordering clinician, who uses the findings to narrow or escalate empiric antibiotics, adjust infection control measures, and inform whether additional testing (e.g., susceptibility testing, molecular testing for gram-negative or fungal targets) is required. Typical sites of service include the hospital clinical microbiology laboratory supporting inpatient care, emergency department, and intensive care unit workflows.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the professional interpretation component of the test if applicable and separable. |